Search results for "Transcytosis"

showing 10 items of 13 documents

Transcytosis of Bacillus subtilis extracellular vesicles through an in vitro intestinal epithelial cell model

2020

Bacterial EVs have been related to inter-kingdom communication between probiotic/pathogenic bacteria and their hosts. Our aim was to investigate the transcytosis process of B. subtilis EVs using an in vitro intestinal epithelial cell model. In this study, using Confocal Laser Scanning Microscopy, we report that uptake and internalization of CFSE-labeled B. subtilis EVs (115 nm ± 27 nm) by Caco-2 cells are time-dependent. To study the transcytosis process we used a transwell system and EVs were quantified in the lower chamber by Fluorescence and Nanoparticle Tracking Analysis measurements. Intact EVs are transported across a polarized cell monolayer at 60–120 min and increased after 240 min …

0301 basic medicineCell Survivalmedia_common.quotation_subjectNanoparticle tracking analysislcsh:MedicineBacillus subtilisCellular imagingmedicine.disease_causeModels BiologicalGastrointestinal epitheliumArticleEpithelium//purl.org/becyt/ford/1 [https]Extracellular Vesicles03 medical and health sciences0302 clinical medicineFunctional FoodmedicineHumansCellular microbiology//purl.org/becyt/ford/1.6 [https]Internalizationlcsh:ScienceCell Proliferationmedia_commonMicroscopy ConfocalMultidisciplinarybiologyChemistryProbioticslcsh:RCell PolarityEpithelial CellsPathogenic bacteriaExtracellular vesiclesbiology.organism_classificationGITIn vitroEpitheliumCell biologyIntestines030104 developmental biologymedicine.anatomical_structureTranscytosis030220 oncology & carcinogenesislcsh:QCaco-2 CellsTranscytosisBacillus subtilisScientific Reports
researchProduct

Candida albicansis able to use M cells as a portal of entry across the intestinal barrierin vitro

2015

Candida albicans is the most frequent yeast responsible for systemic infections in humans. These infections mainly originate from the gastrointestinal tract where C. albicans can invade the gut epithelial barrier to gain access to the bloodstream. Along the gut, pathogens can use Microfold (M) cells as a portal of entry to cross the epithelial barrier. M cells are specialized cells mainly located in the follicule-associated epithelium of Peyer patches. In this study, we used scanning electron and fluorescence microscopy, adhesion and invasion assays and fungal mutants to investigate the interactions of C. albicans with M cells obtained in an established in vitro model whereby enterocyte-lik…

0301 basic medicineCellular differentiationImmunologyBiologyEndocytosisbiology.organism_classificationMicrobiologyIn vitroEpitheliumCorpus albicansMicrobiology03 medical and health sciences030104 developmental biologymedicine.anatomical_structureTranscytosisVirologyImmunologymedicineCandida albicansMicrofold cellCellular Microbiology
researchProduct

The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM

2018

The accumulation of neurotoxic amyloid-beta (Aβ) in the brain is a characteristic hallmark of Alzheimer's disease (AD). The blood-brain barrier (BBB) provides a large surface area and has been shown to be an important mediator for removal of brain Aβ. Both, the ABC transporter P-glycoprotein (ABCB1/P-gp) and the receptor low-density lipoprotein receptor-related protein 1 (LRP1) have been implicated to play crucial roles in Aβ efflux from brain. Here, with immunoprecipitation experiments, co-immunostainings and dual inhibition of ABCB1/P-gp and LRP1, we show that both proteins are functionally linked, mediating a concerted transcytosis of Aβ through endothelial cells. Late-onset AD risk fact…

0301 basic medicineMaleAmyloid betaSwineImmunologyPrimary Cell CultureATP-binding cassette transporterBlood–brain barrierClathrinArticlePICALM03 medical and health sciencesBehavioral NeuroscienceMice0302 clinical medicineAlzheimer DiseasemedicineAnimalsATP Binding Cassette Transporter Subfamily B Member 1Mice KnockoutAmyloid beta-PeptidesbiologyEndocrine and Autonomic SystemsChemistryTumor Suppressor ProteinsPhosphatidylinositol bindingBrainEndothelial CellsLRP1Peptide FragmentsCell biologyDisease Models Animal030104 developmental biologymedicine.anatomical_structureTranscytosisReceptors LDLBlood-Brain BarrierMonomeric Clathrin Assembly Proteinsbiology.proteinTranscytosis030217 neurology & neurosurgeryLow Density Lipoprotein Receptor-Related Protein-1Brain, Behavior, and Immunity
researchProduct

Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates

2018

Abstract Neurological disorders are undoubtedly among the most alarming diseases humans might face. In treatment of neurological disorders, the blood‐brain barrier (BBB) is a challenging obstacle preventing drug penetration into the brain. Advances in dendrimer chemistry for central nervous system (CNS) treatments are presented here. A poly(amido)amine (PAMAM) dendrimer bioconjugate with a streptavidin adapter for the attachment of dendrons or any biotinylated drug is constructed. In vitro studies on porcine or murine models and in vivo mouse studies are performed and reveal the permeation of dendronized streptavidin (DSA) into the CNS. The bioconjugate is taken up mainly by the caveolae pa…

0301 basic medicineStreptavidinblood‐brain barrierGeneral Chemical EngineeringGeneral Physics and AstronomyMedicine (miscellaneous)02 engineering and technologyBlood–brain barrierBiochemistry Genetics and Molecular Biology (miscellaneous)03 medical and health scienceschemistry.chemical_compoundIn vivoDendrimermedicinestreptavidinGeneral Materials SciencePAMAM dendrimerFull PaperGeneral EngineeringFull Papers021001 nanoscience & nanotechnologyIn vitro3. Good health030104 developmental biologymedicine.anatomical_structureTranscytosischemistryBiotinylationDrug deliverydrug deliveryBiophysics0210 nano-technologyAdvanced Science
researchProduct

LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.

2011

According to the "amyloid hypothesis", the amyloid-β (Aβ) peptide is the toxic intermediate driving Alzheimer's disease (AD) pathogenesis. Recent evidence suggests that the low density lipoprotein receptor-related protein 1 (LRP1) transcytoses Aβ out of the brain across the blood-brain barrier (BBB). To provide genetic evidence for LRP1-mediated transcytosis of Aβ across the BBB we analyzed Aβ transcytosis across primary mouse brain capillary endothelial cells (pMBCECs) derived from wild-type and LRP1 knock-in mice. Here, we show that pMBCECs in vitro express functionally active LRP1. Moreover, we demonstrate that LRP1 mediates transcytosis of [(125)I]-Aβ(1-40) across pMBCECs in both direct…

AgingMice 129 StrainEndogenyBiologyEndocytosisBlood–brain barrierchemistry.chemical_compoundMicemedicineAnimalsGene Knock-In TechniquesReceptorCells CulturedAmyloid beta-PeptidesGeneral NeuroscienceTumor Suppressor ProteinsMolecular biologyLRP1Peptide FragmentsBiochemistry of Alzheimer's diseaseCell biologyMice Inbred C57BLmedicine.anatomical_structurechemistryTranscytosisReceptors LDLBlood-Brain BarrierLow-density lipoproteinNeurology (clinical)Geriatrics and GerontologyTranscytosisLow Density Lipoprotein Receptor-Related Protein-1Developmental BiologyNeurobiology of aging
researchProduct

Cellular Prion Protein Participates in Amyloid-β Transcytosis across the Blood—Brain Barrier

2012

The blood—brain barrier (BBB) facilitates amyloid-β (Aβ) exchange between the blood and the brain. Here, we found that the cellular prion protein (PrPc), a putative receptor implicated in mediating Aβ neurotoxicity in Alzheimer's disease (AD), participates in Aβ transcytosis across the BBB. Using an in vitro BBB model, [125I]-Aβ1–40 transcytosis was reduced by genetic knockout of PrPc or after addition of a competing PrPc-specific antibody. Furthermore, we provide evidence that PrPc is expressed in endothelial cells and, that monomeric Aβ1–40 binds to PrPc. These observations provide new mechanistic insights into the role of PrPc in AD.

Amyloid βanimal diseasesBiologyBrief CommunicationBlood–brain barrierModels BiologicalMiceAlzheimer Diseasemental disordersmedicineAnimalsPrPC ProteinsPrion proteinReceptorCells CulturedAmyloid beta-PeptidesNeurotoxicitymedicine.diseaseMolecular biologyPeptide FragmentsIn vitronervous system diseasesCell biologymedicine.anatomical_structureNeurologyTranscytosisBlood-Brain BarrierGene Knockdown Techniquesbiology.proteinNeurology (clinical)AntibodyTranscytosisCardiology and Cardiovascular MedicineProtein BindingJournal of Cerebral Blood Flow & Metabolism
researchProduct

Unraveling In vivo brain transport of protein‐coated fluorescent nanodiamonds

2019

The blood–brain barrier is the biggest hurdle to overcome for the treatment of neurological disorders. Here, protein‐coated nanodiamonds are delivered to the brain and taken up by neurovascular unit cells after intravenous injection. Thus, for the first time, nanodiamonds with their unique properties and a flexible protein coating for the attachment of therapeutics emerge as a potential platform for nanotheranostics of neurological disorders.Nanotheranostics, combining diagnostics and therapy, has the potential to revolutionize treatment of neurological disorders. But one of the major obstacles for treating central nervous system diseases is the blood–brain barrier (BBB) preventing systemic…

Cell SurvivalCentral nervous systemnanotheranosticsTunneling (Physics)Serum Albumin Human02 engineering and technology010402 general chemistryBlood–brain barrier01 natural sciencesFluorescencePolyethylene GlycolsNanodiamondsBiomaterialstunneling nanotubesMiceIn vivoCell MovementmedicineAnimalsBlut-Hirn-SchrankeGeneral Materials Scienceddc:610Blood-brain barrierNeuronsNanotubesChemistryBrainEndothelial CellsBiological TransportGeneral ChemistryHospitals Drug distribution systems021001 nanoscience & nanotechnologyHuman serum albuminPhotobleachingIn vitroEndocytosis0104 chemical sciencesmedicine.anatomical_structureTranscytosisBlood-Brain BarrierNanoröhreAstrocytesDrug deliverydrug deliveryBiophysics0210 nano-technologyDDC 610 / Medicine & healthBiotechnologymedicine.drug
researchProduct

Chapter 7 Cell Protective Functions of Secretory Clusterin (sCLU)

2009

Secretory clusterin (sCLU) is found as an 80-kDa glycoprotein in virtually all body fluids, in serum it is associated with high-density lipoprotein (HDL). Here, we discuss demonstrated and proposed mechanisms of the cytoprotective functions of sCLU in instances of apoptosis, necrosis, and disease. These include prevention from cell damage by lipid oxidation in blood vessels, removal of dead cell remnants in tissues undergoing various forms of cell death, and clearance of harmful extracellular molecules such as amyloid beta (Aβ) by endocytosis or transcytosis. All these functions may reflect the propensity of sCLU to bind to a wide spectrum of hydrophobic molecules on one hand and to specifi…

Cell signalingTranscytosisClusterinbiologyLipid oxidationLDL receptorbiology.proteinSignal transductionReceptorEndocytosisCell biology
researchProduct

Studies on a new potential dopaminergic agent: in vitro BBB permeability, in vivo behavioural effects and molecular docking evaluation.

2015

2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DA-PHEN) has been previously synthesized to obtain a potential prodrug capable of release dopamine (DA) into CNS. However, DA-PHEN could act per se as a dopaminergic drug. In this study, the permeability transport (Pe), obtained by parallel artificial permeability assay (PAMPA), indicated a low passive transcellular transport (Pe = 0.32 ± 0.01 × 10(-6 )cm/s). Using the Caco-2 cell system, the Papp AP-BL in absorptive direction (3.36 ± 0.02 × 10(-5 )cm/s) was significantly higher than the Papp BL-AP in secretive direction (1.75 ± 0.07 × 10(-5 )cm/s), suggesting a polarized transport. The efflux ratio (Papp AP-BL/Papp BL-AP = 0…

DopaminePhenylalanineDopamine AgentsPharmaceutical ScienceMorris water navigation taskPharmacologyBiologyCognitive flexibilityPermeabilityIn vivoDopamineSettore BIO/10 - BiochimicaPAMPA-BBBmedicineHumansIn vivo behavioural effectDopaminergicProdrugSettore CHIM/08 - Chimica FarmaceuticaMolecular Docking SimulationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBlood-Brain BarrierParacellular transportMolecular docking D1-receptorSettore BIO/14 - FarmacologiaEffluxCaco-2 bidirectional assayCaco-2 CellsTranscytosisBehavioural despair testmedicine.drugJournal of drug targeting
researchProduct

Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity.

2012

Abstract The successful non-invasive treatment of diseases associated with the central nervous system (CNS) is generally limited by poor brain permeability of various developed drugs. The blood–brain barrier (BBB) prevents the passage of therapeutics to their site of action. Polymeric drug delivery systems are promising solutions to effectively transport drugs into the brain. We recently showed that amphiphilic random copolymers based on the hydrophilic p(N-(2-hydroxypropyl)-methacrylamide), pHPMA, possessing randomly distributed hydrophobic p(laurylmethacrylate), pLMA, are able to mediate delivery of domperidone into the brain of mice in vivo. To gain further insight into structure–propert…

Drug CarriersPharmaceutical SciencePolymer architectureBiological TransportPharmacologyBlood–brain barrierRhodamine 123Models BiologicalPermeabilityCell Linechemistry.chemical_compoundmedicine.anatomical_structurechemistryTranscytosisIn vivoBlood-Brain BarrierNanoparticles for drug delivery to the brainAmphiphilemedicineHumansMethacrylatesRhodamine 123Barrier functionFluorescent DyesJournal of controlled release : official journal of the Controlled Release Society
researchProduct